BioPharmSignal logoBioPharmSignal

Biotech News

aTyr Pharma Announces One-for-40 Reverse Stock Split

aTyr Pharma (ATYR)aTyr PharmaCompany update

aTyr’s common stock to begin trading on a post-split adjusted basis on October 29, 2026 SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class

Related news

ATYRaTyr Pharma2026-09-01 20:36 EST

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

ATYRaTyr Pharma2026-10-29 12:00 EST

aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine

REGNRegeneron Pharmaceuticals2026-10-26 11:00 EST

Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

IMVTImmunovant2026-10-21 11:00 EST

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

TLSATiziana Life Sciences2026-10-16 11:00 EST

Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease

INMBINmune Bio2026-10-14 12:45 EST

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™

IMMPImmutep Limited2026-10-14 12:00 EST

Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research

SABSSAB Biotherapeutics2026-10-13 12:30 EST

SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes

ENTAEnanta Pharmaceuticals2026-10-13 11:00 EST

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026

BNTXBioNTech2026-10-13 10:45 EST

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer

View all latest news

aTyr Pharma

tRNA Synthetase Biology aTyr Pharma is a clinical-stage biotechnology company translating extracellular signaling functions of tRNA synthetases into therapies for fibrosis and inflammation. Its discovery platform searches domains derived from the 20 human tRNA synthetases for new therapeutic intervention points. Efzofitimod Efzofitimod...

Recent company news

ATYRaTyr Pharma2026-11-05 21:01 EST

aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update

ATYRaTyr Pharma2026-10-29 12:00 EST

aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine

ATYRaTyr Pharma2026-10-27 13:00 EST

aTyr Pharma Announces One-for-40 Reverse Stock Split

ATYRaTyr Pharma2026-10-19 11:00 EST

aTyr Pharma Announces Research Collaboration with Montefiore Einstein

ATYRaTyr Pharma2026-10-13 12:00 EST

aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry

Stock data

Close
6.03 USD
Market cap
50.99M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States